Envision Trials LLC — research payments reported

By program year

4 rows

Year	Kind	Amount	Payments
2025	Research	$881,047	205
2024	Research	$274,214	96
2023	Research	$57,916	5
2022	Research	$2,247	4

Breakdown

Who paid Research payments · program years 2022–2025

ITI, Inc. $559,361 179 payments
AbbVie, Inc. $394,424 33 payments
Neurocrine Biosciences, Inc. $201,477 89 payments
Boehringer Ingelheim Pharmaceuticals, Inc. $55,973 3 payments
Teva Pharmaceuticals USA, Inc. $4,190 6 payments

Studies the money was for Research payments · program years 2022–2025

A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia $322,620 28 payments
Iti-1284-101 $284,245 99 payments
Iti-1284-201 $275,115 80 payments
A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia $201,477 89 payments
A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of?CVL-231?(Emraclidine) in Adult Participants With Schizophrenia $71,804 5 payments
Connex 2 $55,973 3 payments
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia $2,230 3 payments
A Study to Evaluate the Safety, Tolerability, and Effect of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia $1,960 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.